Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

Imatinib mesylate targets mutated KIT oncoproteins in gastrointestinal stromal tumor (GIST) and achieves a clinical response in 80% of patients. The mechanism is believed to depend predominantly on the inhibition of KIT-driven signals for tumor cell survival and proliferation. Using a mouse model of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Balachandran, Vinod P., Cavnar, Michael J., Zeng, Shan, Bamboat, Zubin M., Ocuin, Lee M., Obaid, Hebroon, Sorenson, Eric C., Popow, Rachel, Ariyan, Charlotte, Rossi, Ferdinand, Besmer, Peter, Guo, Tianhua, Antonescu, Cristina R., Taguchi, Takahiro, Yuan, Jianda, Wolchok, Jedd D., Allison, James P., DeMatteo, Ronald P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3278279/
https://ncbi.nlm.nih.gov/pubmed/21873989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.2438
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados